Human Immunology Biosciences
United Kingdom
acquired
acquired
Stage
1
Investors
About
Human Immunology Biosciences was a clinical-stage biotechnology company focused on developing targeted therapies for patients with severe immune-mediated diseases, particularly through its lead asset felzartamab, an investigational therapeutic human monoclonal antibody directed against CD38.
Explore Human Immunology Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.